# Filing Detail

Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001193125-18-128728
Filing Date
2018-04-24
Accepted
2018-04-24 15:57:34
Documents
8
Effectiveness Date
2018-04-24

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFR14A | d573774ddefr14a.htm | DEFR14A | 978488
2 | GRAPHIC | g573774g06d72.jpg | GRAPHIC | 104189
3 | GRAPHIC | g573774g06r49.jpg | GRAPHIC | 114854
4 | GRAPHIC | g573774g23x22.jpg | GRAPHIC | 144132
5 | GRAPHIC | g573774g82k09.jpg | GRAPHIC | 28546
6 | GRAPHIC | g573774g91g84.jpg | GRAPHIC | 57344
7 | GRAPHIC | g573774new01.jpg | GRAPHIC | 382681
8 | GRAPHIC | g573774new02.jpg | GRAPHIC | 184982
| Complete submission text file | 0001193125-18-128728.txt |  | 2369867

Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 000-30171 | Film No.: 18771425
SIC: 2836 Biological Products, (No Diagnostic Substances)